Business
Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients
Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, today announced results from its partnership with Argenica Therapeutics (ASX: AGN) for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke. Analysis using Brainomix 360 Stroke, an FDA-cleared and CE-marked AI-imaging platform, confirmed statistically significant and clinically meaningful efficacy of ARG-007 in severe acut
About this update from Argenica Therapeutics Ltd
[{"type":"list","items":[{"val":[{"type":"text","content":"Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic's Phase II study of neuroprotective ARG-007","length":221,"tagName":"p"}]},{"val":[{"type":"text","content":"Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy analysis","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"The Brainomix AI-enabled analysis demonstrated efficacy of Argenica's ARG-007 in severe stroke patients","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Findings from the analysis will inform future clinical development and patient selection to advance treatment options for patients with severe acute ischemic stroke ","length":164,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":694,"olType":false},{"type":"text","content":"CHICAGO and OXFORD, England, Dec. 18, 2025 /PRNewswire/ -- Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, today announced results from its partnership with Argenica Therapeutics (ASX: AGN) for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke. Analysis using Brainomix 360 Stroke, an FDA-cleared and CE-marked AI-imaging platform, confirmed statistically significant and clinically meaningful efficacy of ARG-007 in severe acute ischemic stroke patients through accurate and standardized quantification of digital imaging biomarkers, including e-ASPECTS which allowed for improved stratification of patients.","length":745,"tagName":"p"},{"type":"image","alt":"Brainomix Logo (PRNewsfoto/Brainomix)","displaySize":"","headline":null,"caption":"Brainomix Logo (PRNewsfoto/Brainomix)","className":"","disableSlideshowImg":false,"size":{"original":{"width":350,"height":144,"url":"https://media.zenfs.com/en/prnewswire.com/31a12e89d7ce77ad010f59615d4b5c62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QDCHl5HI.lwfx7F.iWEFPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI2MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/31a12e89d7ce77ad010f59615d4b5c62","width":350,"height":144}},"...